📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Soluble CTLA-4 attenuates T cell activation and modulates anti-tumor immunity. (2024)

First Author: Kennedy PT

Attributed to: Centre for Drug Safety Science (CDSS) funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.ymthe.2023.11.028

PubMed Identifier: 38053333

Publication URI: http://europepmc.org/abstract/MED/38053333

Type: Journal Article/Review

Volume: 32

Parent Publication: Molecular therapy : the journal of the American Society of Gene Therapy

Issue: 2

ISSN: 1525-0016